Condition: Solid Tumors · Lymphoma · Sponsor: Spectrum Pharmaceuticals, Inc
The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
This description comes directly from the study's public registry record.
Howard Franklin, MD · 224.419.7106 · Hfranklin@assertiotx.com
Always discuss trial participation with your own doctor first.
| New York Medical College | Valhalla, New York, United States | Terminated |
| Carolinas Medical Center/ Levine Children's Hospital | Charlotte, North Carolina, United States | Terminated |
| Levine Children's Health | Charlotte, North Carolina, United States | Terminated |
| University Hospitals Cleveland Medical Center | Cleveland, Ohio, United States | Recruiting |
| UT MD Anderson Cancer Center | Houston, Texas, United States | Terminated |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04570423